Resistive Breathing Versus Inspiratory Hold Technique in Patients With Chronic Bronchitis

Sponsor
Riphah International University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05533931
Collaborator
(none)
26
1
2

Study Details

Study Description

Brief Summary

The aim of the study is to determine the importance and impact of resistive breathing techniques versus inspiratory hold techniques in patients with chronic bronchitis and specially to find out if there are any changes seen in results measured via the incentive spirometer.

Condition or Disease Intervention/Treatment Phase
  • Other: Resistive Breathing Training group
  • Other: inspiratory hold technique
N/A

Detailed Description

Chronic Bronchitis (CB) is defined as a chronic cough and sputum production for at least 3 months a year for 2 consecutive years. It is covered under the umbrella term of Chronic Obstructive Pulmonary Disease (COPD). Chronic bronchitis is thought to be caused by overproduction and hypersecretion of mucus by goblet cells. Epithelial cells lining the airway response to toxic, infectious stimuli by releasing inflammatory mediators and e.g. pro-inflammatory cytokines. During an acute exacerbation of chronic bronchitis, the bronchial mucous membrane becomes hyperemic and edematous with diminished bronchial mucociliary function. This, in turn, leads to airflow impediment because of

luminal obstruction to small airways. The airways become clogged by debris and this further increases the irritation. The characteristic cough of bronchitis is caused by the copious secretion of mucus in chronic bronchitis. Pseudostratified epithelium, highlighting the pseudostratified epithelial cells, goblets cells (shown in blue), then underlying connective tissue.(3) To determine the importance and impact of resistive breathing techniques versus inspiratory hold techniques in patients with chronic bronchitis and specially to find out if there are any changes seen in results measured via incentive spirometer. There are few studies done over it whereas purpose of this research work is to compare these techniques to get better results.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison of Resistive Breathing Versus Inspiratory Hold Technique in Patients With Chronic Bronchitis
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Resistive Breathing Training group

The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device

Other: Resistive Breathing Training group
The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device

Active Comparator: inspiratory hold technique

With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations

Other: inspiratory hold technique
With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations

Outcome Measures

Primary Outcome Measures

  1. oxygen saturation [Changes will be assessed at baseline, 3rd week and 6th weeks measured]

    amount of oxygen traveling through your body with your red blood cells. Changes will be assessed at baseline, 3rd week and 6th weeks measured

  2. Forced expiratory volume in one second [Changes will be assessed at baseline, 3rd week and 6th weeks measured]

    amount of air expired in first one second. Changes will be assessed at baseline, 3rd week and 6th weeks measured

  3. Forced vital capacity [Changes will be assessed at baseline, 3rd week and 6th weeks measured]

    the total amount of air exhaled during the FEV test. Changes will be assessed at baseline, 3rd week and 6th weeks measured

  4. FEV1/FVC ratio [6 weeks]

    the amount of air exhaled in the first second divided by all of the air exhaled during a maximal exhalation.

  5. shortness of breath measured through borge scale of dyspnea [Changes will be assessed at baseline, 3rd week and 6th weeks measured]

    shortness of breath. Changes will be assessed at baseline, 3rd week and 6th weeks measured

  6. SGRQ questionnaire [Changes will be assessed at baseline, 3rd week and 6th weeks measured]

    how breathing problems effects quality of life . Changes will be assessed at baseline, 3rd week and 6th weeks measured

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • • Diagnosed with chronic bronchitis

  • Clinically stable patients.

  • Both genders.

  • Age 45 to 60 years.

  • Pink puffers included in this study

  • Clients that are involved in research are not allowed for other interventional therapies. They can take their regular medications.

  • Patients diagnosed at least 2 years ago with bronchitis.

Exclusion Criteria:
  • • Presence of any genetic disorders (cystic fibrosis).

  • Recent spinal / chest surgery

  • Cardiac issues

  • Fractures of vertebra caused by osteoporosis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo hospital Lahore Punjab Pakistan 53700

Sponsors and Collaborators

  • Riphah International University

Investigators

  • Principal Investigator: Wajeeha Zia, MSPT, Riphah International University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Riphah International University
ClinicalTrials.gov Identifier:
NCT05533931
Other Study ID Numbers:
  • RiphahB Muhammad Makhdoom
First Posted:
Sep 9, 2022
Last Update Posted:
Sep 9, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Riphah International University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 9, 2022